{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:54:45Z","timestamp":1791568485096,"version":"4.3.4"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100017981","name":"Sysmex Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017981","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.exphem.2026.105488","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:18:16Z","timestamp":1785770296000},"page":"105488","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Peripheral Blood Profiles Reflecting Progenitor Lineage Balance are Associated With Molecular Response in Chronic Myeloid Leukemia"],"prefix":"10.1016","volume":"162","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-6772-4882","authenticated-orcid":false,"given":"Kohjin","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6377-0174","authenticated-orcid":false,"given":"Naoki","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Tsukune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9618-6588","authenticated-orcid":false,"given":"Tadaaki","family":"Inano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8871-1330","authenticated-orcid":false,"given":"Miki","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6493-6225","authenticated-orcid":false,"given":"Tomoiku","family":"Takaku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2026.105488_bib0001","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature."},{"key":"10.1016\/j.exphem.2026.105488_bib0002","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/BF01630378","article-title":"The minute chromosome (Phl) in chronic granulocytic leukemia","volume":"8","author":"Nowell","year":"1962","journal-title":"Blut."},{"key":"10.1016\/j.exphem.2026.105488_bib0003","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/315550a0","article-title":"Fused transcript of abl and bcr genes in chronic myelogenous leukaemia","volume":"315","author":"Shtivelman","year":"1985","journal-title":"Nature"},{"issue":"14","key":"10.1016\/j.exphem.2026.105488_bib0004","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med."},{"issue":"6","key":"10.1016\/j.exphem.2026.105488_bib0005","doi-asserted-by":"crossref","first-page":"657","DOI":"10.3324\/haematol.2016.142877","article-title":"Innovation in hematology. Perspectives: CML 2016","volume":"101","author":"Hehlmann","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2026.105488_bib0006","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia."},{"issue":"8","key":"10.1016\/j.exphem.2026.105488_bib0007","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/s41375-025-02664-w","article-title":"2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia","volume":"39","author":"Apperley","year":"2025","journal-title":"Leukemia."},{"issue":"2","key":"10.1016\/j.exphem.2026.105488_bib0008","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11899-016-0309-2","article-title":"Long-term side effects of tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"11","author":"Caldemeyer","year":"2016","journal-title":"Curr Hematol Malig Rep"},{"issue":"2","key":"10.1016\/j.exphem.2026.105488_bib0009","first-page":"597","article-title":"Improving chronic myeloid leukemia management and quality of life: patient and physician survey on unmet needs from the CML SUN survey","volume":"111","author":"Lang","year":"2026","journal-title":"Haematologica."},{"issue":"11","key":"10.1016\/j.exphem.2026.105488_bib0010","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.exphem.2026.105488_bib0011","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejca.2017.02.028","article-title":"Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A systematic review and a meta-analysis","volume":"77","author":"Campiotti","year":"2017","journal-title":"Eur J Cancer."},{"key":"10.1016\/j.exphem.2026.105488_bib0012","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1182\/blood.2020005514","article-title":"Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia","volume":"137","author":"Shanmuganathan","year":"2021","journal-title":"Blood."},{"key":"10.1016\/j.exphem.2026.105488_bib0013","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1002\/cncr.31187","article-title":"Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase","volume":"124","author":"Sasaki","year":"2018","journal-title":"Cancer."},{"key":"10.1016\/j.exphem.2026.105488_bib0014","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/leu.2015.261","article-title":"Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia","volume":"30","author":"Pfirrmann","year":"2016","journal-title":"Leukemia."},{"key":"10.1016\/j.exphem.2026.105488_bib0015","article-title":"Treatment- free remission in chronic myeloid leukemia and new approaches by targeting leukemia stem cells","volume":"11","author":"Chen","year":"2021","journal-title":"Front Oncol."},{"key":"10.1016\/j.exphem.2026.105488_bib0016","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/wsbm.86","article-title":"Hematopoietic stem cell: self-renewal versus differentiation","volume":"2","author":"Seita","year":"2010","journal-title":"Wiley Interdiscip Rev Syst Biol Med."},{"key":"10.1016\/j.exphem.2026.105488_bib0017","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.stem.2007.07.004","article-title":"Reciprocal activation of GATA-1 and PU.1 marks initial specification of hematopoietic stem cells into myeloerythroid and myelolymphoid lineages","volume":"1","author":"Arinobu","year":"2007","journal-title":"Cell Stem Cell."},{"issue":"7","key":"10.1016\/j.exphem.2026.105488_bib0018","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1056\/NEJMoa040258","article-title":"Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML","volume":"351","author":"Jamieson","year":"2004","journal-title":"N Engl J Med."},{"issue":"6394","key":"10.1016\/j.exphem.2026.105488_bib0019","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1126\/science.aan0096","article-title":"Ghost cytometry","volume":"360","author":"Ota","year":"2018","journal-title":"Science."},{"issue":"3","key":"10.1016\/j.exphem.2026.105488_bib0020","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/cas.16424","article-title":"BCR::ABL1-induced mitochondrial morphological alterations as a potential clinical biomarker in chronic myeloid leukemia","volume":"116","author":"Suzuki","year":"2025","journal-title":"Cancer Sci."},{"key":"10.1016\/j.exphem.2026.105488_bib0021","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-06664-9","article-title":"Artificial intelligence-driven label-free detection of chronic myeloid leukemia cells using ghost cytometry","volume":"15","author":"Suzuki","year":"2025","journal-title":"Sci Rep."},{"key":"10.1016\/j.exphem.2026.105488_bib0022","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ipm.2009.03.002","article-title":"A systematic analysis of performance measures for classification tasks","volume":"45","author":"Sokolova","year":"2009","journal-title":"Inf Process Manag."},{"issue":"1","key":"10.1016\/j.exphem.2026.105488_bib0023","doi-asserted-by":"crossref","first-page":"5979","DOI":"10.1038\/s41598-022-09954-8","article-title":"On evaluation metrics for medical applications of artificial intelligence","volume":"12","author":"Hicks","year":"2022","journal-title":"Sci Rep."},{"issue":"3","key":"10.1016\/j.exphem.2026.105488_bib0024","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transpl."},{"key":"10.1016\/j.exphem.2026.105488_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12308-022-00484-w","article-title":"Evaluation of immature granulocyte parameters in myeloid neoplasms assayed by Sysmex XN hematology analyzer","volume":"15","author":"Lu","year":"2022","journal-title":"J Hematop."},{"key":"10.1016\/j.exphem.2026.105488_bib0026","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.67660","article-title":"In silico-labeled ghost cytometry","volume":"10","author":"Ugawa","year":"2021","journal-title":"Elife"},{"key":"10.1016\/j.exphem.2026.105488_bib0027","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/s12185-025-04132-8","article-title":"Development of a blood test-based predictive scoring tool for treatment response in chronic myeloid leukemia","volume":"123","author":"Suzuki","year":"2026","journal-title":"Int J Hematol. Int J Hematol."},{"key":"10.1016\/j.exphem.2026.105488_bib0028","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S0092-8674(03)00191-0","article-title":"A myristoyl\/phosphotyrosine switch regulates c-Abl","volume":"112","author":"Hantschel","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2026.105488_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2020.106458","article-title":"The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase","volume":"98","author":"Manley","year":"2020","journal-title":"Leuk Res."},{"key":"10.1016\/j.exphem.2026.105488_bib0030","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1056\/NEJMoa2400858","article-title":"Asciminib in Newly Diagnosed Chronic Myeloid Leukemia","volume":"391","author":"Hochhaus","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.exphem.2026.105488_bib0031","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41375-023-01829-9","article-title":"Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL","volume":"37","author":"Hochhaus","year":"2023","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.exphem.2026.105488_bib0032","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.3324\/haematol.2023.284860","article-title":"The initial molecular response predicts the deep molecular response but not treatment-free remission maintenance in a real-world chronic myeloid leukemia cohort","volume":"109","author":"Saugues","year":"2024","journal-title":"Haematologica."},{"key":"10.1016\/j.exphem.2026.105488_bib0033","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1200\/JCO.23.01647","article-title":"European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in chronic myeloid leukemia: final analysis and novel prognostic factors for treatment-free remission","volume":"42","author":"Mahon","year":"2024","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.exphem.2026.105488_bib0034","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1084\/jem.20041535","article-title":"Dynamic regulation of PU.1 expression in multipotent hematopoietic progenitors","volume":"201","author":"Nutt","year":"2005","journal-title":"J Exp Med."},{"key":"10.1016\/j.exphem.2026.105488_bib0035","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nri2024","article-title":"Transcription factors in myeloid development: balancing differentiation with transformation","volume":"7","author":"Rosenbauer","year":"2007","journal-title":"Nat Rev Immunol."},{"key":"10.1016\/j.exphem.2026.105488_bib0036","doi-asserted-by":"crossref","first-page":"12355","DOI":"10.1073\/pnas.93.22.12355","article-title":"Arrested development of embryonic red cell precursors in mouse embryos lacking transcription factor GATA-1","volume":"93","author":"Fujiwara","year":"1996","journal-title":"Proc Natl Acad Sci U A."},{"key":"10.1016\/j.exphem.2026.105488_bib0037","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S1074-7613(02)00452-1","article-title":"Cooperative and antagonistic interplay between PU.1 and GATA-2 in the specification of myeloid cell fates","volume":"17","author":"Walsh","year":"2002","journal-title":"Immunity."},{"key":"10.1016\/j.exphem.2026.105488_bib0038","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.immuni.2007.06.004","article-title":"Myeloid lineage commitment from the hematopoietic stem cell","volume":"26","author":"Iwasaki","year":"2007","journal-title":"Immunity."},{"key":"10.1016\/j.exphem.2026.105488_bib0039","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/ajcp\/107.6.661","article-title":"CD16 antigen density on neutrophils in chronic myeloproliferative disorders","volume":"107","author":"Kabutomori","year":"1997","journal-title":"Am J Clin Pathol."},{"key":"10.1016\/j.exphem.2026.105488_bib0040","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1038\/s41375-025-02769-2","article-title":"Granulocyte abundance and maturation state at diagnosis predicts treatment-free remission in CML","volume":"39","author":"Purhonen","year":"2025","journal-title":"Leukemia."},{"key":"10.1016\/j.exphem.2026.105488_bib0041","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s12185-021-03117-7","article-title":"Treatment-free remission and immunity in chronic myeloid leukemia","volume":"113","author":"Ureshino","year":"2021","journal-title":"Int J Hematol."},{"key":"10.1016\/j.exphem.2026.105488_bib0042","doi-asserted-by":"crossref","first-page":"5594","DOI":"10.3390\/jcm11195594","article-title":"Immunomodulatory effects of IFN\u03b1 on T and NK cells in chronic myeloid leukemia patients in deep molecular response preparing for treatment discontinuation","volume":"11","author":"Puzzolo","year":"2022","journal-title":"J Clin Med."},{"key":"10.1016\/j.exphem.2026.105488_bib0043","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.71142","article-title":"Clinical features and T-cell repertoire of chronic myeloid leukemia patients who attempt discontinuation of tyrosine kinase inhibitors: the ISAC-TFR study","volume":"14","author":"Ureshino","year":"2025","journal-title":"Cancer Med."},{"issue":"4","key":"10.1016\/j.exphem.2026.105488_bib0044","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood."}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X26001219?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X26001219?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:23:50Z","timestamp":1791566630000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X26001219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":44,"alternative-id":["S0301472X26001219"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2026.105488","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peripheral Blood Profiles Reflecting Progenitor Lineage Balance are Associated With Molecular Response in Chronic Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2026.105488","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Experimental Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105488"}}